CINGULATE,INC

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: $17M

Website

Clinical Trials

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

Phase 3

Suspended

Conditions: Attention Deficit Hyperactivity Disorder
Attention-deficit Hyperactivity
ADHD
ADHD - Combined Type
Attention Deficit Disorder With Hyperactivity
Attention Deficit Hyperactivity Disorder Combined
Attention Deficit Hyper Activity

Interventions: Drug: CTx-1301 - Dexmethylphenidate 6.25mg
Drug: Placebo
Drug: CTx-1301 - Dexmethylphenidate 12.5mg
Drug: CTx-1301 - Dexmethylphenidate 18.75mg
Drug: CTx-1301 - Dexmethylphenidate 25.0mg
Drug: CTx-1301 - Dexmethylphenidate 31.25mg
Drug: CTx-1301 - Dexmethylphenidate 37.5mg

First Posted Date: 2023-06-29

Last Posted Date: 2024-08-16

Lead Sponsor: Cingulate Therapeutics

Target Recruit Count: 45

Registration Number: NCT05924594

Locations: 🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸
Accel Research Sites, Maitland, Florida, United States
🇺🇸
Center for Psychiatry & Behavioral Medicine, Las Vegas, Nevada, United States

Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder
ADHD
ADHD - Combined Type
Attention Deficit Hyperactivity Disorder Combined

Interventions: Drug: CTx-1301 - Dexmethylphenidate 25mg
Drug: CTx-1301 - Dexmethylphenidate 37.5mg
Drug: Placebo
Drug: CTx-1301 - Dexmethylphenidate 50mg

First Posted Date: 2022-11-30

Last Posted Date: 2023-06-22

Lead Sponsor: Cingulate Therapeutics

Target Recruit Count: 21

Registration Number: NCT05631626

Locations: 🇺🇸
Clinical Research of Southern Nevada, LLC, Las Vegas, Nevada, United States

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

Phase 3

Terminated

Conditions: ADHD
Attention Deficit Hyperactivity Disorder
Attention-deficit Hyperactivity
Attention Deficit Hyper Activity
ADHD - Combined Type
Attention Deficit Hyperactivity Disorder Combined

Interventions: Drug: CTx-1301-Dexmethylphenidate 12.5 mg (titration only)
Drug: Placebo
Drug: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)
Drug: CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
Drug: CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)

First Posted Date: 2022-03-18

Last Posted Date: 2024-08-15

Lead Sponsor: Cingulate Therapeutics

Target Recruit Count: 103

Registration Number: NCT05286762

Locations: 🇺🇸
Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
🇺🇸
BioBehavioral Research of Austin, Austin, Texas, United States
🇺🇸
Sisu Bhr, Llc, Springfield, Massachusetts, United States

and more 19 locations

Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers in Fed and Fasted State

Interventions: Drug: Dexmethylphenidate

First Posted Date: 2020-06-26

Last Posted Date: 2022-10-20

Lead Sponsor: Cingulate Therapeutics

Target Recruit Count: 27

Registration Number: NCT04449250

Locations: 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States

CTx-1301 Comparative Bioavailability Study

Phase 1

Completed

Conditions: ADHD

Interventions: Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release
Drug: Dexmethylphenidate 6.25 mg Tablet
Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
Drug: Dexmethylphenidate 50 mg Tablet

First Posted Date: 2019-10-24

Last Posted Date: 2021-04-08

Lead Sponsor: Cingulate Therapeutics

Target Recruit Count: 45

Registration Number: NCT04138498

Locations: 🇺🇸
Vince & Associates, Overland Park, Kansas, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy